Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

29 oct. 2014 05h30 HE | Source: Achaogen, Inc.

Achaogen to Present at 2014 Credit Suisse Healthcare Conference

SOUTH SAN FRANCISCO, Oct. 29, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR)...
17 sept. 2014 05h30 HE | Source: Achaogen, Inc.

Achaogen Announces First Patient Enrollment in a Phase 3 Clinical Trial of Plazomicin to Treat Infections Caused by Carbapenem-Resistant Enterobacteriaceae (CRE)

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
11 août 2014 16h15 HE | Source: Achaogen, Inc.

Achaogen Announces Second Quarter 2014 Results

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
14 juil. 2014 05h30 HE | Source: Achaogen, Inc.

Achaogen Appoints Dr. Ian Friedland as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., July 14, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
12 mai 2014 08h00 HE | Source: Achaogen, Inc.

Achaogen Announces First Quarter 2014 Results

SOUTH SAN FRANCISCO, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
07 avr. 2014 05h30 HE | Source: Achaogen, Inc.

Achaogen to Present at 13th Annual Needham Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 7, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
02 avr. 2014 05h30 HE | Source: Achaogen, Inc.

Achaogen Appoints Chris Boerner to Board of Directors

SOUTH SAN FRANCISCO, Calif., April 2, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
17 mars 2014 11h55 HE | Source: Achaogen, Inc.

Achaogen Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., March 17, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
12 mars 2014 05h30 HE | Source: Achaogen, Inc.

Achaogen Announces Pricing of Initial Public Offering

SOUTH SAN FRANCISCO, Calif., March 12, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc., a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR)...